C12N 2710/10045
Special targeting system for viral vectors
C12N2710/10045 (Special targeting system for viral vectors) appears on 12 US grants and 24 published applications in this corpus.
Search patents in C12N- Granted patents
- 12
- Published applications
- 24
- Assignees
- 18
- Inventors
- 61
- Latest grant
- 21 Jan 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 1 | 0 |
| 2002 | 0 | 1 |
| 2003 | 1 | 2 |
| 2004 | 1 | 0 |
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 1 | 0 |
| 2009 | 1 | 0 |
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 1 |
| 2016 | 1 | 2 |
| 2017 | 0 | 3 |
| 2018 | 3 | 4 |
| 2019 | 0 | 1 |
| 2020 | 0 | 1 |
| 2021 | 1 | 2 |
| 2022 | 0 | 1 |
| 2023 | 1 | 1 |
| 2024 | 0 | 0 |
| 2025 | 1 | 2 |
By publication year.
Recent patents
- Viral gene therapy as treatment for cholesterol storage disease or disorder21 Jan 2025US 12,201,658 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- CRISPR-associated (Cas) proteins with reduced immunogenicity31 Jan 2023US 11,566,052 B2Lonza Ltd.
- AAV8 mutant capsids and compositions containing same17 Aug 2021US 11,091,776 B2The Trustees of the University of Pennsylvania
- Pharmaceutical composition comprising Nanog shRNA, and method of using Nanog shRNA to treat cancer5 Jun 2018US 9,988,631 B2The United States of America, as represented by the Secretary, Dept. of Health and Human Services
- Penton-mutated, integrin-retargeted adenovirus vectors with reduced toxicity and their use29 May 2018US 9,982,276 B2Adcure Biotechnologies, LLC.
- Compositions and methods for retinal neuron generation25 Sep 2025US 2025/0297281 A1University of Utah Research Foundation
- Viral gene therapy as treatment for cholesterol storage disease or disorder22 May 2025US 2025/0161383 A1The United States of America, as represented by the Secretary, Department of Health and Human Servi
- Therapeutic peptide composition and methods of treatment26 Oct 2023US 2023/0340043 A1
- Pharmaceutical agent for inducing specific immunity against sars-cov-221 Jul 2022US 2022/0226466 A1
- Novel aav8 mutant capsids and compositions containing same4 Nov 2021US 2021/0340569 A1The Trustees of the University of Pennsylvania
Most cited
By later US patents
- Method for the production and purification of adenoviral vectors110US 6,194,191 B1Introgen Therapeutics, Inc. · 2001
- Purified adenoviral compositions53US 6,726,907 B1Introgen Therapeutics, Inc. · 2004
- Modification of virus tropism and host range by viral genome shuffling34US 6,596,539 B1Maxygen, Inc. · 2003
- Method for the production and purification of adenoviral vectors34US 7,445,930 B2Introgen Therapeutics, Inc. · 2008
- Methods for producing purified adenoviral vectors33US 7,510,875 B2Introgen Therapuetics, Inc. · 2009